Michael Goldberg, Surge Therapeutics CEO

Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

Every year, mil­lions of can­cer pa­tients un­der­go surgery to get their tu­mors re­moved. But while re­sec­tion can stave off can­cer for some time, as many as 40% of pa­tients would even­tu­al­ly see their can­cer re­turn — and suc­cumb to the dis­ease.

Among them were Michael Gold­berg’s friends. And he does not find it ac­cept­able.

Hav­ing trained with Bob Langer and Phillip Sharp at MIT for his PhD and post­doc, Gold­berg left a fac­ul­ty po­si­tion at Har­vard four years ago to launch Surge Ther­a­peu­tics based on his lab’s work on a hy­dro­gel tech that can be in­ject­ed di­rect­ly in­to the tu­mor site post-re­sec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.